Selecting an appropriate model of supervision for foundation trainees

How to identify and implement a model of supervision that gets the most out of the designated supervisor and designated prescribing practitioner roles.
Pharmaceutical person talking with doctor in medical building

After reading this article, you should be able to:

  • Understand the purpose and structure of prescribing supervision during the foundation training year;
  • Identify the different supervision models that can be used to support the 90 hours of prescribing-related learning;
  • Recognise the roles and responsibilities of designated supervisors and designated prescribing practitioners, including how these work in both single-sector and multisector placements.

According to the General Pharmaceutical Council’s (GPhC) Standards for the Initial Education and Training of Pharmacists, newly qualified pharmacists registering from 2026 onwards will be independent prescribers at the point of registration​1​

NHS England’s workforce, training and education directorate oversees the management and quality assurance of the foundation training year, including prescribing supervision and assessment. A central requirement is that foundation trainee pharmacists in England must complete a minimum of 90 hours of supervised prescribing-related learning, supported by a designated prescribing practitioner (DPP) and a designated supervisor (DS).

Effective models of supervision will be crucial in supporting trainees to meet the required prescribing competencies safely and confidently. This article outlines the different supervision models that may be adopted in foundation training, with guidance on how they function in both single-sector and multi-sector training pathways. It also explores practical strategies for ensuring clear communication, appropriate delegation, and collaborative working between DS and DPP.

The article focuses on supervision models and eligibility requirements as they apply to foundation trainee pharmacists undertaking their training in England, where programmes are managed by NHS England’s workforce, training and education directorate. Different arrangements and requirements exist in the other UK nations, where foundation training is overseen by their respective education bodies:

Trainees, supervisor and DPPs in these nations should refer to their national guidance for details specific to foundation training and assessment.

Requirements for being a designated supervisor or prescribing practitioner

While the requirements for a DS remain unchanged from previous years, the introduction of the DPP role and its associated eligibility criteria is a new development within the foundation programme, reflecting the distinct nature of prescribing supervision. Figure 1 summarises the eligibility requirements as outlined by NHS England​2​.

The requirements for a DPP supervising a foundation trainee are distinct from those for a DPP supporting a qualified pharmacist undertaking an independent prescribing course, reflecting the different levels of prescribing complexity involved​2,3​. The main difference is that the ‘three-year rule’ — the requirement for at least three years’ recent prescribing experience — does not apply to DPPs supervising foundation trainee pharmacists​2,3​. This is because prescribing by newly qualified pharmacists, after completing foundation training programme, is expected to be more limited in scope and complexity, carried out with prescribing support and supervision, whereas qualified pharmacists undertaking prescribing training typically manage more complex clinical situations within a broader or specialist scope of practice.

When an individual meets both role specifications, they may act as both DS and DPP; however, the GPhC requires that more than one registrant is involved in the assessment of a trainee pharmacist. Therefore, if the same person acts as both DS and DPP, another prescriber must contribute to the trainee’s assessment.

The trainee must complete at least 90 hours of supervised learning to develop and demonstrate prescribing-related skills. The DPP can enlist the support of other healthcare professionals (known as practice supervisors) to support some of this learning time where appropriate; however, they must personally supervise the trainee enough to ensure that they are able to make an informed decision about their prescribing capability.  

Supervisors are encouraged to complete formal preparation for their roles. DSs may undertake educational supervisor training via e-Learning for Healthcare (eLfH) or other locally accredited courses. For DPPs, the Collaborative of Learning progamme (eight modules) and SCRIPT e-learning are currently recognised options.

Models of supervision

The GPhC and NHS England permit flexible models of supervision, so training sites can choose approaches best suited to their context, staffing and placement design​2​. Each model has benefits and limitations, meaning that choosing the most effective structure requires careful planning. The ‘best’ model will be dependent on the training programme (e.g. multisector or unisector), nominated prescribing area and availability of supervisors at the training site. 

Both the DS and DPP are responsible for the successful completion of the foundation training by a trainee pharmacist. The DS will make the final sign-off decision for the learning outcomes and the DPP will do the same for the prescribing activities. 

A selection of possible models are summarised below.

Model 1: Pharmacist DS with a medical DPP

This model has been widely used in independent prescribing (IP) training for qualified pharmacists. In this model, the DS is a pharmacist and the DPP is a doctor — often a general practitioner or secondary-care consultant. The medical DPP may be based in the same workplace as the trainee or outside the main training place.

The following case examples illustrates how this model can be deployed in practice.

Case 1: Pharmacist DS with a medical DPP

Training programme: Community pharmacy 39 weeks, general practice 13 weeks.

DPP: General practitioner (GP).

Scope of practice: Cardiovascular preventative medicines.

Supervision arrangement: The accountability for the prescribing and DPP was within the primary-care placement. The trainee had DS in secondary care, DS and DPP in GP practice.

Prescribing hours: Over 90 hours (90 hours with DPP (1 day/week over 13 weeks) and some hours with other prescribers (including pharmacist and nurses).

The accountability for the prescribing and DPP was within the primary care placement. The trainee had a DS in community pharmacy and a DS in primary care, in addition to the DPP. The primary-care DS organised prescribing activities with other prescribers in the GP practice; this included a pharmacist-led lipid management and hypertension clinic and other long-term-condition clinics with nurse prescribers. Completed activities included audit completion in community pharmacy linked to the scope of prescribing, prescribing safety activities with the pharmacist in primary care and supervised learning events (SLEs) in both settings linked to the scope of the prescribing. 

Model 2: Pharmacist DS with nurse or allied healthcare professional DPP

In this model, the DPP is a nurse or allied health professional with an independent prescribing annotation. While less commonly used in IP training for pharmacists, it may offer practical advantages, particularly in settings where a non-medical prescriber is the clinical lead in a nominated prescribing area.

Case 2: Pharmacist DS with a nurse or allied health professional DPP

Training programme: 52-week secondary-care placement.

DPP: Heart-failure specialist IP nurse.

Scope of practice: Pharmacological management of chronic heart failure. 

Prescribing hours: 90 hours completed (30% with DPP: 30 hours and 60 hours with other prescribers in secondary care, including doctors and pharmacists).

The prescribing activities included time with DPP (in both a heart failure clinic and reviewing heart failure inpatients on the ward), time with specialist heart failure pharmacist, completion of an audit linked to the scope of practice, attending ward rounds, attending MDTs, and undertaking SLEs linked to the scope of practice. Regular tripartite meetings with the trainee, DS and DPP were essential to discuss progress and address any concerns at the earliest opportunity. 

Model 3: Pharmacist DS with a pharmacist DPP (two individuals)

This model may be increasingly common as more pharmacists become prescribers. Here, the DS and DPP are different pharmacists — potentially in the same or different organisations. This model can be an option when the DS is a pharmacist but may not yet meet the criteria to act as a DPP, with another pharmacist who does meet the criteria acting as the DPP. This model also could work well in multisector rotations, where focused prescribing activities are completed during multisector rotation with DPP provision. 

Case 3: Pharmacist DS with a pharmacist DPP (two individuals)

Training programme: Secondary care 39 weeks/GP practice 13 weeks.

DPP: IP pharmacist working in a GP practice.

Scope of practice: Type 2 diabetes mellitus oral medication.

Prescribing hours: Over 90 hours completed (50% with DPP and 50% with others).

The accountability for the prescribing and DPP was within the primary-care placement. Both the DS and DPP were present at all progress-review meetings. The prescribing activities included time with: 

  • DPP (in both a diabetes clinic and undertaking other prescribing safety-related activities);
  • Specialist endocrinology pharmacist in secondary care;
  • Other prescribers within the GP practice (including medical and AHPs); 
  • Attending a medical ward round (secondary care);
  • Completion of audit linked to the scope of practice (GP practice);
  • Attending safety prescribing meetings and other MDT meetings (GP practice); 
  • Undertaking SLEs linked to the scope of practice (GP practice and secondary care). 

Model 4: Pharmacist DS and DPP (same person)

When a pharmacist meets the criteria for both roles, they may act as both DS and DPP. This model may become more prevalent over time as more pharmacists qualify as prescribers and integrated training models become established.

Case 4: Pharmacist DS and DPP (same person)

Training programme: Secondary care 39 weeks, GP practice 13 weeks.

DPP:  IP pharmacist working in a secondary care.

Scope of practice: 90 hours (60% with DPP: 15 hours in primary care, 75 hours in secondary care).

Prescribing hours: Anticoagulation

The accountability for the prescribing and DPP was within the secondary care placement. The trainee pharmacist was still able to complete some prescribing training in primary care and was able to log prescribing activities. Having the accountability with the secondary-care DPP/DS was beneficial when planning and creating a personal development plan. This worked successfully owing to regular three-way meetings with the practice supervisor and training pharmacist when the trainee was in primary care.

Considerations for multisector training programmes 

As multisector training programmes are increasing in popularity and will become a mandatory requirement going forward, foundation trainee pharmacists will have multiple DSs​4​. According to GPhC guidance, DSs should be in place for placements lasting longer than 13 weeks; however, only one DPP may be nominated per trainee. Where trainees are undertaking their foundation training year across multiple sectors, it will be important to ensure that the DPP is in the sector where most of the prescribing experience is likely to occur, and also that there are clear lines of communication so that evidence generated in a different sector can be taken into account when considering sign-off for the trainee.

Trainees completing a sandwich or practice-intercalated course will need to consider any supervision requirements specific to that programme. For example, the five-year sandwich MPharm programme at the University of Bradford includes two six-month placements either side of the fourth year of academic study enabling students to undertake foundation training as part of the programme.  This means students will need to have a different DS and DPP for each of their six-month placements. This may also be necessary when a supervisor leaves the host organisation or is absent, such as on parental or sick leave. It will be very important in these cases to ensure that communication between the different supervisors is clear, timely and well documented, so that trainees don’t have to unnecessarily repeat activities and supervised practice hours. 

Fostering strong supervision and communication

It is important to ensure effective communication and collaborative planning between the trainee, all DSs and the DPP. Trainees are more likely to successfully demonstrate prescribing competence when early meetings are held to assess learning needs, required actions and jointly plan how the 90 hours of supervised learning in practice will be used​5​. These regular, three-way progress meetings should be scheduled to continue throughout the foundation training year to ensure that everyone involved is aware of how the trainee is progressing allowing any remedial action to be taken if required.

It is important to take the time to consider and agree on which methods of three-way communication will work best for each specific supervision arrangement. A range of digital tools is available to support collaboration, even when supervisors are based in different locations or organisations; for example, video conferencing, shared editable documents (e.g. Google Docs), messaging apps and email. However, when using these tools, it is essential to ensure compliance with privacy, data protection and local organisational policies. Clear expectations and boundaries should be established from the outset to maintain professional standards and ensure all parties are aligned. 

Troubleshooting

Even if communication is established well from the beginning, some issues may arise over the course of the foundation training programme. The table below provides some examples of possible challenges and how they can be approached based on learnings from the NHS England independent prescribing  pilot programme​3​

Summary

A successful prescribing supervision model is grounded in shared goals, role clarity and adaptability to the training context. Whether within a single site or across sectors, the choice of supervision model should prioritise the trainee’s learning experience, regulatory requirements and feasibility of sustained collaboration between supervisors. As the prescribing landscape in pharmacy evolves and greater emphasis is placed on pharmacist-led training and interprofessional collaboration, these models will continue to adapt.


  1. 1.
    Standards for the initial education and training of pharmacists. General Pharmaceutical Council. 2021. Accessed July 2025. https://assets.pharmacyregulation.org/files/2024-01/Standards%20for%20the%20initial%20education%20and%20training%20of%20pharmacists%20January%202021%20final%20v1.4.pdf
  2. 2.
    Prescribing Supervision and Assessment in the Foundation Trainee Pharmacist Programme from 2025/26. NHS England. 2024. Accessed July 2025. https://www.hee.nhs.uk/sites/default/files/documents/Prescribing%20Supervision%20and%20Assessment%20in%20the%20Foundation%20Trainee%20Pharmacist%20Programme%20JAN%202024%20V1.2.pdf
  3. 3.
  4. 4.
    Foundation Trainee Pharmacist Programme: Practice-based Assessment Strategy (from 2025/26). NHS England. 2024. Accessed July 2025. https://www.hee.nhs.uk/sites/default/files/documents/NHS%20England%20Foundation%20Trainee%20Pharmacist%20Practice-based%20Assessment%20Strategy%20for%202025%2026_V1.1%20March%202025.docx
  5. 5.
    Achi P, Denby T, Kavanaugh S, et al. Evaluation report: Independent Prescribing Pilot Programme during Foundation Training for Trainee Pharmacists. Health Education England. 2024. Accessed July 2025. https://www.hee.nhs.uk/sites/default/files/documents/NHSE%20WTE%20Independent%20Prescribing%20Pilot%20Evaluation%20Report.pdf
Last updated
Citation
The Pharmaceutical Journal, PJ, July 2025, Vol 315, No 7999;315(7999)::DOI:10.1211/PJ.2025.1.362947

    Please leave a comment 

    You might also be interested in…